Sanofi’s Wayrilz, the first BTK inhibitor to treat immune thrombocytopenia gets European approval: Paris Saturday, December 27, 2025, 12:00 Hrs [IST] Sanofi, an R&D driven, AI-p ...

Imagine watching a conversation between brain cells, seeing chemical messages pass from one neuron to another. Scientists can ...

In a striking demonstration of automated chemistry, researchers have used a robotic synthesis platform to rapidly generate ...

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

Metal.com reported lithium spodumene concentrate Index (Li2O 5.5%-6.2%, excluding tax/insurance/freight) spot price of USD ...

Nova Minerals is locking in fresh funding to accelerate work at its flagship 9.9Moz Estelle gold and critical minerals ...

Scilex Holding Company ('Scilex” or the 'Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for ...

The high-profile, much-debated arena renovation provided an upbeat note in the city at a time when the challenges of soaring ...

After years in the wings, hydropower stepped into the spotlight in 2025. Policymakers began to value the grid-balancing power ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...